Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Insights, 2017 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Insights, 2017" drug pipelines to their offering.

Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Insights, 2017 provides in depth insights on the pipeline drugs and their development activities around the Vaginal Atrophy (Atrophic Vaginitis).

This report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details.

This report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Vaginal Atrophy (Atrophic Vaginitis). This report also assesses the Vaginal Atrophy (Atrophic Vaginitis) therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Key Topics Covered:

  1. Vaginal Atrophy (Atrophic Vaginitis) Overview
  2. Vaginal Atrophy (Atrophic Vaginitis) Pipeline Therapeutics
  3. Vaginal Atrophy (Atrophic Vaginitis) Therapeutics under Development by Companies
  4. Vaginal Atrophy (Atrophic Vaginitis) Filed and Phase III Products
  5. Vaginal Atrophy (Atrophic Vaginitis) Phase II Products
  6. Vaginal Atrophy (Atrophic Vaginitis) Phase I and IND Filed Products
  7. Vaginal Atrophy (Atrophic Vaginitis) Discovery and Pre-Clinical Stage Products
  8. Drug Candidate Profiles
  9. Vaginal Atrophy (Atrophic Vaginitis) - Therapeutics Assessment
  10. Assessment by Monotherapy Products
  11. Assessment by Combination Products
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Vaginal Atrophy (Atrophic Vaginitis) - Discontinued Products
  15. Vaginal Atrophy (Atrophic Vaginitis) - Dormant Products
  16. Companies Involved in Therapeutics Development for Vaginal Atrophy (Atrophic Vaginitis)

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/gkv84h/vaginal_atrophy

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Women's Health, Sexual and Reproductive Health Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Women's Health, Sexual and Reproductive Health Drugs